S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Price, News & Analysis

$15.36
+0.41 (+2.74%)
(As of 03/27/2024 ET)
Today's Range
$14.70
$15.56
50-Day Range
$13.92
$19.50
52-Week Range
$8.13
$43.69
Volume
713,708 shs
Average Volume
1.32 million shs
Market Capitalization
$548.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.63

Biomea Fusion MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
242.6% Upside
$52.63 Price Target
Short Interest
Bearish
40.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Biomea Fusion in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.29) to ($3.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

833rd out of 939 stocks

Biotechnology Industry

18th out of 25 stocks

BMEA stock logo

About Biomea Fusion Stock (NASDAQ:BMEA)

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

BMEA Stock Price History

BMEA Stock News Headlines

BMEA Apr 2024 5.000 put
BMEA Apr 2024 5.000 call
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
Wall Street Expects 190% Upside for This Biotech Stock
Buy Rating Affirmed for Biomea Fusion Amid Promising Clinical Trials
Biomea Fusion Inc BMEA
Biomea Fusion's Uphill Battle In Diabetes Care
See More Headlines
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BMEA
Fax
N/A
Employees
103
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.63
High Stock Price Target
$90.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+242.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-81,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.69 per share

Miscellaneous

Free Float
26,326,000
Market Cap
$548.51 million
Optionable
Optionable
Beta
-0.48
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

BMEA Stock Analysis - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares.
View BMEA analyst ratings
or view top-rated stocks.

What is Biomea Fusion's stock price target for 2024?

8 brokerages have issued 12-month price objectives for Biomea Fusion's shares. Their BMEA share price targets range from $33.00 to $90.00. On average, they predict the company's stock price to reach $52.63 in the next twelve months. This suggests a possible upside of 242.6% from the stock's current price.
View analysts price targets for BMEA
or view top-rated stocks among Wall Street analysts.

How have BMEA shares performed in 2024?

Biomea Fusion's stock was trading at $14.52 at the beginning of the year. Since then, BMEA shares have increased by 5.8% and is now trading at $15.36.
View the best growth stocks for 2024 here
.

Are investors shorting Biomea Fusion?

Biomea Fusion saw a increase in short interest in March. As of March 15th, there was short interest totaling 11,200,000 shares, an increase of 6.9% from the February 29th total of 10,480,000 shares. Based on an average daily volume of 976,000 shares, the days-to-cover ratio is currently 11.5 days. Approximately 40.6% of the shares of the company are short sold.
View Biomea Fusion's Short Interest
.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.04.

What ETF holds Biomea Fusion's stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 113,300 shares of BMEA stock, representing 1.44% of its portfolio.

When did Biomea Fusion IPO?

Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.78%), Vanguard Group Inc. (3.78%), Northern Trust Corp (0.62%), Charles Schwab Investment Management Inc. (0.50%), Price T Rowe Associates Inc. MD (0.49%) and Price T Rowe Associates Inc. MD (0.49%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends
.

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMEA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners